BriaCell Therapeutics (TSX: BCT) KOL Event: Bria-IMT™ Potential in Advanced Metastatic Breast Cancer
About The Event
BriaCell Virtual KOL Event Agenda – October 26, 2023
- Dr. William Williams (CEO) – Introduction and opening remarks
- Dr. Giuseppe Del Priore (CMO) – Event agenda and KOL introductions
- Dr. Adam Brufsky (KOL) – Review all metastatic breast cancer and current treatment landscape
- Dr. Saranya Chumsri (KOL) – Bria-IMT™ Clinical data to date & Phase 3 clinical study details
- Drs. Del Priore and Williams – Summary and next steps
Join BriaCell Therapeutics (TSX: BCT) for a virtual event featuring KOLs Adam M. Brufsky, MD, PhD, FACP (University of Pittsburgh School of Medicine) and Saranya Chumsri, MD (Mayo Clinic) who will discuss the unmet medical need and current treatment landscape for patients suffering from advanced metastatic breast cancer, along with the combination study of Bria-IMT™ with immune check point inhibitor.
BriaCell leadership will provide a pipeline overview and highlight the next steps for the Phase 3 study. Bria-IMT™ has been awarded Fast Track status by the U.S Food and Drug Administration for the treatment of advanced metastatic breast cancer.
A live question and answer session will follow the formal presentations.